🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07191626
Starting soon Not applicable

Pulsed Field Ablation of SVC and PV in Paroxysmal Atrial Fibrillation (PASPA Study)

NCT07191626 · tracked via the Priya Life Science China tracker
Sponsor
Changhai Hospital
Phase
Not applicable
Started
2025-11-01
Last updated
2025-09-25

Condition(s) studied

Paroxysmal Atrial FibrillationParoxysmal Atrial Fibrillation (PAF)

Investigational drug(s) / intervention(s)

PFA - PV + SVCIPFA - PVI only

PFA - PV + SVCI: Catheter ablation procedure using a Pulsed Field Ablation system to achieve electrical isolation of all four pulmonary veins AND the superior vena cava.

PFA - PVI only: Catheter ablation procedure using a Pulsed Field Ablation system to achieve electrical isolation of all four pulmonary veins only. No ablation is performed in the superior vena cava.

Study summary

The PASPA study is a multicenter, randomized trial comparing Pulmonary Vein Isolation (PVI) alone versus PVI plus Superior Vena Cava Isolation (SVCI) using Pulsed Field Ablation (PFA) in patients with paroxysmal atrial fibrillation (PAF).

650 participants will be followed for 12 months. The main goal is to see if adding SVCI reduces arrhythmia recurrence without increasing complications such as phrenic nerve injury or sinus node dysfunction.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Documented paroxysmal AF (episodes self-terminating within 7 days), evidenced by ECG, Holter, or event monitor 2. Age between 18 and 80 years 3. Willing and able to provide written informed consent Exclusion Criteria: 1. Intracardiac thrombus (left atrium or left atrial appendage) 2. Left atrial anterior-posterior diameter \> 60 mm 3. Absolute contraindication to anticoagulation therapy 4. Stroke or myocardial infarction within 1 month prior to enrollment 5. Uncontrolled hyperthyroidism 6. Pregnancy or planning pregnancy 7. Life expectancy less than 1 year 8. Previous atrial fibrillation ablation procedure 9. Known or suspected AF triggers primarily originating from the SVC (based on pre-procedure mapping, if available) 10. Inability or unwillingness to participate in the study or comply with follow-up requirements

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital). No. 168, Changhai Road, Yangpu District, Shanghai, China. Shanghai Shanghai Municipality

More Changhai Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07191626 on ClinicalTrials.gov ↗ ← All trials in China